Abstract |
Integrin α5β1 is an important therapeutic target that can be inhibited using an aldolase antibody (Ab)-derived chemical-Ab (chem-Ab) for the treatment of multiple human diseases, including cancers. A fairly optimized anti- integrin α5β1 chem-Ab 38C2-4e was obtained using an in situ convergent chemical programming (CP) approach, which minimized the time and effort needed to develop a chem-Ab. Multiple Ab-programming agents (PAs) 4a-e could be prepared rapidly using the Cu-catalyzed alkyne- azide coupling (Cu-AAC) reaction of an α5β1 inhibitor 2 with multiple linkers 3a-e, either before or after conjugating the linkers into Ab 38C2 binding sites. In these two-steps processes, the products after step 1 can be used in the next step without performing an extensive purification or analysis of the Ab-PAs or Ab-linker conjugates affording chem-Abs 38C2-(4a-e). Flow cytometry assay was used to determine the binding of the chem-Abs to U87 human glioblastoma cells expressing α5β1 integrin and identify 38C2-3e as the strongest binder. Further studies revealed that 38C2-3e strongly inhibited proliferation of U87 cells and tube formation of HUVEC in the matrigel assay, as well as tumor growth and metastasis of 4T1 cells in vivo.
|
Authors | Rajib K Goswami, Yuan Liu, Cheng Liu, Richard A Lerner, Subhash C Sinha |
Journal | Molecular pharmaceutics
(Mol Pharm)
Vol. 10
Issue 2
Pg. 538-43
(Feb 04 2013)
ISSN: 1543-8392 [Electronic] United States |
PMID | 23102054
(Publication Type: Journal Article, Research Support, N.I.H., Extramural)
|
Chemical References |
- Antineoplastic Agents
- Immunoglobulin Fab Fragments
- Integrin alpha5beta1
- antibody aldolase
- Fructose-Bisphosphate Aldolase
|
Topics |
- Antineoplastic Agents
(chemical synthesis, chemistry, pharmacology)
- Cell Line, Tumor
- Cell Proliferation
(drug effects)
- Flow Cytometry
- Fructose-Bisphosphate Aldolase
(chemistry)
- Humans
- Immunoglobulin Fab Fragments
(chemistry)
- Integrin alpha5beta1
(antagonists & inhibitors)
|